OncoMatch/Clinical Trials/NCT06767514
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Is NCT06767514 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Ivonescimab and Pembrolizumab for non-small cell lung cancer.
Treatment: Ivonescimab · Pembrolizumab — Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) high expression (tps >50%) (tps >50%)
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
No prior systemic treatment for metastatic NSCLC.
Cannot have received: any prior therapy for NSCLC in the metastatic setting
Has received any prior therapy for NSCLC in the metastatic setting.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clinical Study Site · Chandler, Arizona
- Clinical Study Site · Phoenix, Arizona
- Clinical Study Site · Hot Springs, Arkansas
- Clinical Study Site · Cerritos, California
- Clinical Study Site · Glendale, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify